AI Powerhouses & Sorintellis Forge Alliance to Remake Clinical Trials

MONTREAL, QC – April 07, 2026 – A strategic collaboration announced today aims to reshape the costly and time-consuming process of clinical drug development by creating a new AI-powered intelligence layer. Montreal-based startup Sorintellis is joining forces with leading academic institutions and industry partners to accelerate its mission of making clinical trials more efficient and predictable.

The partnership brings Sorintellis together with Vantage Biotrials, Université de Montréal, Université Laval, and the data science institute IVADO. This alliance seeks to leverage cutting-edge artificial intelligence to optimize every stage of the drug development pipeline, from initial trial design to final portfolio strategy.

At the heart of the initiative is Sorintellis's proprietary dataset, TrialsBank™, which will serve as the foundation for developing sophisticated recommendation engines. The ultimate goal is to create a structural shift in how therapies are developed, promising faster and more robust pathways to bring safer and more effective treatments to patients globally.

The Brains Behind the Breakthrough

This collaboration establishes a formidable multidisciplinary team, uniting industry know-how with academic rigor. The academic firepower comes from a trio of prominent researchers, all with ties to the world-renowned Mila – Quebec Artificial Intelligence Institute.

The team includes Prof. Marc-André Legault of Université de Montréal, whose work focuses on computational drug target validation; Prof. Mireille Schnitzer, also from Université de Montréal, a specialist in biostatistics and causal inference; and Prof. Audrey Durand from Université Laval, an expert in reinforcement learning and its application in healthcare.

Their combined expertise spans reinforcement learning, causal inference, biostatistics, and medical machine learning—a suite of advanced AI disciplines essential for untangling the complex web of factors that determine a clinical trial's success or failure. This fusion of different AI approaches is critical for moving beyond simple predictive models and creating systems that can actively recommend optimal paths forward.

Vantage BioTrials, a Canadian Contract Research Organization (CRO), brings crucial real-world operational expertise to the table. Their deep experience in managing clinical trials ensures that the AI solutions developed will be pragmatic and directly applicable to the challenges faced by pharmaceutical companies and researchers on the ground.

Unlocking TrialsBank™: The Engine for Smarter Development

Founded in 2022, Sorintellis has a bold mission to "D.O.P.E. the Pharma Pipeline"—to help organizations Design, Optimize, Prioritize, and Execute drug development programs with greater precision. The company is building what it calls the "intelligence infrastructure for clinical drug development."

Central to this vision is TrialsBank™, a deeply curated and validated clinical development dataset. Unlike public databases, TrialsBank™ integrates a vast array of trial data enriched with scientific, clinical, operational, regulatory, and even financial features. This multi-layered dataset provides the rich context necessary for AI models to understand the subtle drivers of trial outcomes.

The collaboration will use this data to build advanced recommendation engines. These are not merely predictive tools that forecast a trial's probability of success. Instead, they are designed to be prescriptive, helping decision-makers optimize trial design, streamline operational workflows, assess risk more accurately, and make high-stakes portfolio decisions with greater confidence. This initiative builds on a previous successful proof-of-concept project Sorintellis undertook with Vantage BioTrials and the Computer Research Institute of Montreal (CRIM).

"This collaboration marks a pivotal step toward transforming clinical development into a truly data-driven, intelligence-powered infrastructure," said Emmanuel Piffo, Founder and CEO at Sorintellis, in the original announcement.

Navigating a Crowded Field

The push to integrate AI into clinical trials is part of a massive industry-wide trend. The global market for AI in clinical trials was valued at approximately $1.3 billion in 2023 and is projected to skyrocket to over $4.4 billion by 2032, according to some market reports. An estimated 75% of pharmaceutical companies are already integrating AI into their trial processes.

Sorintellis enters a competitive landscape populated by established giants like Medidata and IQVIA, as well as specialized AI players such as Unlearn.ai, which creates "digital twins" of patients, and Intelligencia AI, which also focuses on predicting trial success. As a relatively young, unfunded company, Sorintellis's strategy of forging deep scientific partnerships appears to be a key differentiator.

While the company has not completed a formal funding round, it has received project-based support. A previous project was backed by CQDM, with support from the Quebec government, to develop an AI-powered platform for analyzing clinical trial success, demonstrating early confidence in its approach. This new, larger collaboration significantly amplifies its research and development capabilities, allowing it to compete by deepening its scientific foundation rather than through sheer capital.

From Code to Cure: The Ultimate Goal for Patients

Behind the technical complexity of AI models and datasets lies a simple, powerful objective: improving human health. The inefficiencies of the current drug development paradigm are well-known, with high failure rates and staggering costs that ultimately limit the number of new therapies that reach patients.

By optimizing clinical trials, this AI-driven approach could lead to significant benefits. Industry analyses suggest AI applications could reduce drug development timelines and costs by 25% to 50%. For patients, this translates into quicker access to potentially life-saving treatments. For the healthcare system, it means more efficient allocation of R&D resources toward the most promising candidates.

However, the path to adoption is not without its hurdles. Regulatory bodies like the U.S. Food and Drug Administration (FDA) and European authorities are carefully scrutinizing the use of AI in medicine. They are developing frameworks to ensure that algorithms are validated, transparent, and free from biases that could compromise patient safety or trial integrity. The deep involvement of academic experts in biostatistics and causal inference in the Sorintellis collaboration is a strategic move that directly addresses these concerns, emphasizing a commitment to rigor and interpretability that will be crucial for earning regulatory and public trust.